Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at HC Wainwright from $12.00 to $5.00. They now have a "neutral" rating on the stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $33.00 to $15.00. They now have an "outperform" rating on the stock.
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Royal Bank of Canada from $7.00 to $6.00. They now have a "sector perform" rating on the stock.